FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
1-Year Return
24.36%
This Quarter Return
+7.12%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$222M
AUM Growth
+$78.9M
(+55%)
Cap. Flow
+$64.6M
Cap. Flow
% of AUM
29.14%
Top 10 Holdings %
Top 10 Hldgs %
89.9%
Holding
16
New
3
Increased
8
Reduced
3
Closed
1
Top Buys
| 1 |
Insmed
INSM
|
+$20.7M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$16.4M |
| 3 |
Arcus Biosciences
RCUS
|
+$10M |
| 4 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
+$7.59M |
| 5 |
Arbutus Biopharma
ABUS
|
+$6.67M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
+$3.53M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$1.85M |
| 3 |
uniQure
QURE
|
+$1.77M |
| 4 |
Denali Therapeutics
DNLI
|
+$1.48M |
Sector Composition
| 1 | Healthcare | 92.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$29.8B
| $40.5M | 16.8% |
1,799,225
+919,315
| +104% | +$20.7M |
|
|
2
Ascendis Pharma
ASND
$11.9B
| $31.1M | 12.89% |
475,419
-53,924
| -10% | -$3.53M |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $27.4M | 11.37% |
2,111,869
-142,633
| -6% | -$1.85M |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $21.9M | 9.09% |
851,200
+637,765
| +299% | +$16.4M |
|
|
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $19.1M | 7.93% |
391,955
+82,598
| +27% | +$4.03M |
|
|
IMMU
6
DELISTED
Immunomedics Inc
IMMU
| $15.7M | 6.5% |
1,073,272
| – | – |
|
|
7
uniQure
QURE
$837M
| $13.2M | 5.46% |
560,073
-75,161
| -12% | -$1.77M |
|
|
ALDR
8
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $10.6M | 4.38% |
830,919
+598,010
| +257% | +$7.59M |
|
|
9
Arcus Biosciences
RCUS
$1.22B
| $10M | 4.16% |
+650,000
| New | +$10M |
|
|
OPTN
10
DELISTED
OptiNose
OPTN
| $9.68M | 4.01% |
32,240
+2,240
| +7% | +$673K |
|
11
Aclaris Therapeutics
ACRS
$200M
| $7.53M | 3.12% |
429,551
+177,615
| +71% | +$3.11M |
|
|
12
Arbutus Biopharma
ABUS
$842M
| $7.43M | 3.08% |
1,485,245
+1,334,653
| +886% | +$6.67M |
|
13
Rhythm Pharmaceuticals
RYTM
$6.37B
| $3.98M | 1.65% |
200,000
+25,000
| +14% | +$498K |
|
|
RARX
14
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $2.39M | 0.99% |
+450,000
| New | +$2.39M |
|
15
Solid Biosciences
SLDB
$430M
| $1.05M | 0.44% |
+9,355
| New | +$1.05M |
|
|
16
Denali Therapeutics
DNLI
$2B
| – | – |
-94,666
| Closed | -$1.48M |
|